Doravirine is a novel, potent, HIV-1 non-nucleoside reverse transcriptase inhibitor that is primarily metabolized by oxidation via CYP3A4. A previous clinical trial demonstrated that co-administration of doravirine with multiple dose (MD) rifampin, a strong CYP3A4 inducer, resulted in decreased doravirine exposure. This study assessed the impact of MD rifabutin administration, a moderate CYP3A4 inducer, on the pharmacokinetics (PK) of doravirine.
This was an open-label, 2-period, fixed-sequence study in healthy adult subjects. In Period 1 (P1), a single dose (SD) of 100 mg doravirine was administered on Day 1. In Period 2 (P2), following a 7-day washout, rifabutin 300 mg was administered once daily for 16 days and co-administered with 100 mg doravirine on Day 14. Blood samples to measure doravirine concentrations were collected through 72 hours post-dose in P1 and P2.
Eighteen subjects (15 male and 3 female) were enrolled. Following co administration with MD rifabutin, doravirine Cmax was not affected; however, exposure and C24 values were reduced. The geometric mean ratios (90% confidence intervals) [doravirine + MD rifabutin/doravirine] for Cmax, AUC0-∞, and C24hr were 0.99 (0.85, 1.15), 0.50 (0.45, 0.55), and 0.32 (0.28, 035), respectively. There were no serious adverse experiences (AEs) and most AEs were mild in intensity. Three (16.7%) and 16 (94.1%) subjects reported at least 1 AE in P1 and P2, respectively. Most AEs in P2 were related to rifabutin treatment. The most common AEs were headache (1 subject in P1 and 8 subjects in P2) and fever (7 subjects in P2). Six subjects discontinued (DC’d) the study due to AEs: in P1, 1 subject was DC’d due to elevated GGT; in P2, prior to receiving doravirine, 5 subjects were DC’d due to fever with or without other flu-like signs and symptoms.
Doravirine was generally well tolerated when administered alone or with rifabutin. Multiple dosing of rifabutin significantly reduced doravirine AUC0-∞ and C24 via CYP3A4 induction. However, increasing the dose of doravirine above the clinical dose of 100 mg may mitigate the interaction such that rifabutin, and other moderate CYP3A4 inducers, may be co-administered with doravirine.